We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BD DIAGNOSTIC SYSTEMS

BD Diagnostics manufactures and markets medical supplies and devices and diagnostic systems that include cellular ana... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Tumor Markers Reveal Lethality of Bladder Cancers

By LabMedica International staff writers
Posted on 17 Nov 2016
Print article
Image: The BD LSRFortessa flow cytometer cell analyzer (Photo courtesy of Becton Dickinson).
Image: The BD LSRFortessa flow cytometer cell analyzer (Photo courtesy of Becton Dickinson).
Bladder cancer is the fourth most common cause of cancer-related death among men in the USA and more than 75,000 new cases will be diagnosed this year and more than 16,000 people will die from this disease.

Tumor cells collected during the removal of a cancerous bladder and in some cases transplanted into mice with weakened immune systems could help physicians rapidly identify high-risk cancers, determine prognosis and refine the use of biomarkers to personalize care for patients with this common cancer.

Medical scientists at the University of Chicago Medical Center (Chicago, IL, USA) obtained tumor samples from 71 bladder cancer patients treated at the University and used flow cytometry to isolate and count specific subtypes of tumor cells in each sample. A portion of the tumor was separated for xenograft injection. The remaining tissue was disaggregated in Miltenyi gentleMACS tube tissue dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany), then enzymatically treated using DNase and Liberase.

Single-cell suspensions of patient tumor tissue were stained using antibodies and flow cytometry was performed using the BD LSRFortessa and BD LSR-II and cells were sorted using BD FACSAriaIII. Flow sorted cells as well as samples of cells from the bulk tumor were collected and ribonucleic acid (RNA) was extracted and assayed in duplicate using Illumina HumanHT-12 v4 Expression BeadChip microarrays.

The team found that detection of poorly differentiated basal tumor cells (BTC) in early stage cancers; overexpression in those cells of a gene known as cell division cycle 25C, which plays a key role in the regulation of cell division; or the ability of tumor fragments to grow when transplanted into a mouse, all predicted an increased risk of death. Analyzing the global expression of genes in BTCs, they also identified a potentially prognostic biomarker for bladder cancer: cell division cycle 25C (CDC25C), a protein that drives cell division. An expanded analysis, including 400 bladder cancer patients, found that the expression of this protein is associated with an increased risk of death even after the removal of the cancerous bladder.

This association disappeared in patients who had previously received chemotherapy. A test for CDC25C could, the authors suggest, help determine whether a bladder cancer patient is likely to benefit from drug treatment. Ralph Weichselbaum, MD, a professor and senior author of the study said, “Prognostic knowledge can change a lot about how you choose to treat a cancer. We may be able to avoid aggressive measures if we find a tumor has relatively few basal cells, But if a bladder tumor has a lot of basal cells, we may need to take the entire bladder out and follow that with chemotherapy.” The study was published on October 24, 2016, in the journal Scientific Reports.

Related Links:
University of Chicago Medical Center
Miltenyi Biotec
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.